Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @ExelixisInc
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ExelixisInc
-
At Exelixis, cancer is our cause. In honor of
#WorldCancerDay
, see how some of our employees are committed to helping tackle difficult-to-treat-cancers and learn more about the #IAmAndIWill
campaign at https://bit.ly/2tsZ2VL .pic.twitter.com/b58zkX0Jfi
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Caring for a loved one with
#cancer can require a lot of help. Learn how to facilitate a productive family meeting so no one person is left feeling overwhelmed.pic.twitter.com/WsZnKjBaByHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our partner
@TakedaPharma applied for regulatory approval of$EXEL lead therapy for previously treated advanced#livercancer in Japan. Learn more http://bit.ly/2O8KcuF .pic.twitter.com/vcIb92i825
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
In the US, approximately 42,000 new cases of
#livercancer were diagnosed in 2019. Learn about the COSMIC-312 clinical trial at Booth 64#GI20 and explore more at http://COSMIC312.com .pic.twitter.com/fxxcIhTox3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Explore the COSMIC-021 clinical trial investigating different cancers, including certain GI cancers. See us at
#GI20 and visit our website at http://COSMIC021.com .pic.twitter.com/wxFRmVlc7f
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Last year approximately 42,000 cases of
#livercancer were diagnosed. Learn more about this disease.#GI20pic.twitter.com/OdQempOaJ4Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Data from phase 1/2 CheckMate 040
#livercancer trial to be presented at#GI20 now in the Level 2 Ballroom.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Just announced: Phase 1/2 CheckMate 040 trial results for
$EXEL lead product and immunotherapy combo in advanced#livercancer: https://bit.ly/2U3Y11x .#GI20pic.twitter.com/UDdMqBXtY2
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Exelixis is at
#GI20 with our clinical trial for#livercancer. Explore more at Booth 64 and visit http://COSMIC312.com .pic.twitter.com/6IJR7Fr2dI
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#GI20 starts today! We look forward to discussing our latest research in gastrointestinal#cancers. Visit Exelixis at booth #64 to learn more.pic.twitter.com/tWXt2F3GNF
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
People who are overweight have a higher risk of developing
#kidneycancer and#livercancer. Here are some habits that may help maintain a healthy weight this#HealthyWeightWeek.pic.twitter.com/4ZaXXOOpScHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we remember Dr. Martin Luther King Jr. for his commitment to social justice and community service.
#MLKDay
pic.twitter.com/IiyQHoEvvN
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Honored to present at the
@jpmorgan Healthcare Conference this week and connect with the financial community and industry leaders.#JPM20pic.twitter.com/x0mGS6ZBIs
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Investors:
$EXEL to present at the@jpmorgan Healthcare Conference today at 4:30 PM PT. Details: https://bit.ly/2R8wj0t .#JPM20pic.twitter.com/Lv1PaZiHbH
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We’re excited to welcome the community to San Francisco for the 38th Annual
@jpmorgan Healthcare Conference this week. We look forward to discussing the future of oncology care.#JPM20pic.twitter.com/95TzxGugxK
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ahead of
#JPM20, we’ve announced our key corporate priorities and anticipated pivotal clinical milestones for the next two years, as well as preliminary Q4/FY’19$EXEL financial results and 2020 guidance. Details here: http://bit.ly/2Nl77Tg .pic.twitter.com/GhrtWFsNOe
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ATTN investors:
$EXEL to present at the@jpmorgan Healthcare Conference in San Francisco. Details here: https://bit.ly/2Fq95xl .#JPM20pic.twitter.com/AN51kPPTmz
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We’re further expanding the
#prostatecancer cohort in our$EXEL phase 1b COSMIC-021 trial. Learn more in our latest announcement: https://bit.ly/2T0XPzy .pic.twitter.com/FSqb3bQkwE
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#HappyNewYear! 2019 was an opportunity for us to reflect on the progress we have made for patients over the past 25 years. We look forward to carrying this momentum forward into 2020.pic.twitter.com/5dm7wUPCCG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Considering making New Year’s resolutions? Some of the most common are related to health and may help lower cancer risk. Learn more.pic.twitter.com/UcmtY5NsXI
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.